Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.41 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 3/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13925377 | 0.83 | NAMPT (0.47) | SLC6A15NAMPTCCR1KCNH2HRH3 | |
| SCHEMBL12049583 | 0.77 | HPGD (0.40) | NAMPTCCR1KCNH2HRH3 | |
| SCHEMBL12285971 | 0.75 | NOTUM (0.34) | NAMPTKCNH2HRH3 | |
| SCHEMBL13515399 | 0.74 | RBP4 (0.41) | NAMPTCCR1KCNH2HRH3 | |
| SCHEMBL19981883 | 0.74 | DPP4 (0.44) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL19454524 | 0.73 | HRH3 (0.35) | NAMPTKCNH2HRH3 | |
| SCHEMBL19982010 | 0.73 | DPP4 (0.43) | DPP4DPP7DPP8DPP9SLC6A15 | |
| SCHEMBL8261115 | 0.73 | QDPR (0.49) | NAMPT | |
| SCHEMBL16809856 | 0.73 | MAPT (0.41) | KCNH2HRH3 | |
| SCHEMBL14243055 | 0.72 | ATM (0.46) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | DPP4 3504/4885DPP7 4157/4885DPP8 4369/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | DPP4 3757/4885DPP7 4144/4885DPP8 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.